A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8524 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8524-8524 ◽

Author(s):

Owen A. O'Connor ◽

Changchun Deng ◽

Jennifer Effie Amengual ◽

Mazen Y. Khalil ◽

Marshall T. Schreeder ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

B Cell ◽

Hodgkin Lymphoma ◽

Phase I Trial ◽

Prior Exposure ◽

Non Hodgkin Lymphoma ◽

Download Full-text

Faculty Opinions recommendation of A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727328356.793538169 ◽

2017 ◽

Author(s):

Varsha Gandhi ◽

Prithviraj Bose

Keyword(s):

Monoclonal Antibody ◽

Chronic Lymphocytic Leukaemia ◽

B Cell ◽

Hodgkin Lymphoma ◽

Lymphocytic Leukaemia ◽

Phase 1 ◽

Non Hodgkin Lymphoma ◽

Download Full-text

CD20 antibodies: type II to tango?

Blood ◽

10.1182/blood-2012-04-420711 ◽

2012 ◽

Vol 119 (22) ◽

pp. 5061-5063 ◽

Author(s):

Marinus H. J. van Oers

Keyword(s):

Monoclonal Antibody ◽

B Cell ◽

Hodgkin Lymphoma ◽

Type Ii ◽

Non Hodgkin Lymphoma ◽

Anti Cd20 ◽

Intense Research ◽

Cd20 Antibodies

Although the chimeric anti-CD20 monoclonal antibody (mAb) rituximab has revolutionized the treatment of B-cell non-Hodgkin lymphoma (NHL), still many patients relapse and an increasing number become refractory to rituximab-containing therapy. This has initiated intense research to develop more potent anti-CD20 antibodies.

Download Full-text

Abstract CT146: First-in-human phase I combination of the IL-15 receptor super agonist complex ALT-803 with a therapeutic (anti-CD20) monoclonal antibody (mAb) for patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)

10.1158/1538-7445.am2018-ct146 ◽

2018 ◽

Author(s):

Todd A. Fehniger ◽

Brian T. Hess ◽

Veronika Bachanova ◽

Michelle Becker-Hapak ◽

Ethan McClain ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Hodgkin Lymphoma ◽

Non Hodgkin Lymphoma ◽

Download Full-text

Anti-CD20 Monoclonal Antibody (Rituximab) for Therapy of Mediastinal CD20-Positive Large B-Cell Non-Hodgkin Lymphoma with a Local Tumor Extension into the Lung of a 10-Year-Old Girl

Pediatric Hematology and Oncology ◽

10.1080/08880010390203125 ◽

2003 ◽

Vol 20 (4) ◽

pp. 339-344 ◽

Author(s):

Srdjana Čulić ◽

Vida Čulić ◽

Visnja Armanda ◽

Dubravka Kuljiš ◽

Valdi Pešutić-Pisac ◽

...

Keyword(s):

Monoclonal Antibody ◽

B Cell ◽

Hodgkin Lymphoma ◽

Local Tumor ◽

Tumor Extension ◽

Non Hodgkin Lymphoma ◽

Anti Cd20 ◽

Download Full-text

A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-12-3349 ◽

2013 ◽

Vol 19 (13) ◽

pp. 3659-3670 ◽

Author(s):

Razelle Kurzrock ◽

Peter M. Voorhees ◽

Corey Casper ◽

Richard R. Furman ◽

Luis Fayad ◽

...

Keyword(s):

Multiple Myeloma ◽

Monoclonal Antibody ◽

Phase I ◽

B Cell ◽

Hodgkin Lymphoma ◽

Castleman Disease ◽

Open Label Study ◽

Label Study ◽

Non Hodgkin Lymphoma

Download Full-text

LONG-TERM OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON- HODGKIN LYMPHOMA TREATED WITH BISPECIFIC ANTIBODY BLINATUMOMAB IN A PHASE I TRIAL

Hematological Oncology ◽

10.1002/hon.136_2630 ◽

2019 ◽

Vol 37 ◽

pp. 325-326

Author(s):

V. Dufner ◽

C. Sayheli ◽

G. Gelbrich ◽

R. Bargou ◽

M. Goebeler

Keyword(s):

Phase I ◽

B Cell ◽

Hodgkin Lymphoma ◽

Phase I Trial ◽

Bispecific Antibody ◽

Term Outcome ◽

Long Term Outcome ◽

Non Hodgkin Lymphoma

Download Full-text

Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-1339 ◽

2009 ◽

Vol 15 (20) ◽

pp. 6446-6453 ◽

Author(s):

Stephen M. Ansell ◽

Sara A. Hurvitz ◽

Patricia A. Koenig ◽

Betsy R. LaPlant ◽

Brian F. Kabat ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

B Cell ◽

Hodgkin Lymphoma ◽

Phase I Study ◽

Non Hodgkin Lymphoma

Download Full-text

A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

British Journal of Haematology ◽

10.1111/bjh.14534 ◽

2017 ◽

Vol 177 (2) ◽

pp. 243-253 ◽

Author(s):

Ahmed Sawas ◽

Charles M. Farber ◽

Marshall T. Schreeder ◽

Mazen Y. Khalil ◽

Daruka Mahadevan ◽

...

Keyword(s):

Monoclonal Antibody ◽

Chronic Lymphocytic Leukaemia ◽

B Cell ◽

Hodgkin Lymphoma ◽

Lymphocytic Leukaemia ◽

Phase 1 ◽

Non Hodgkin Lymphoma ◽

Download Full-text

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma

American Journal of Hematology ◽

10.1002/ajh.23460 ◽

2013 ◽

Vol 88 (7) ◽

pp. 589-593 ◽

Author(s):

Thomas E. Witzig ◽

Gregory A. Wiseman ◽

Matthew J. Maurer ◽

Thomas M. Habermann ◽

Ivana N.M. Micallef ◽

...

Keyword(s):

Phase I ◽

B Cell ◽

Hodgkin Lymphoma ◽

Phase I Trial ◽

Ibritumomab Tiuxetan ◽

Non Hodgkin Lymphoma

Download Full-text

Phase I and pharmacokinetics study of a novel anti-CD20 antibody, RO5072759 (GA101), in Japanese patients (Pts) with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.e18552 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. e18552-e18552

Author(s):

K. Tobinai ◽

M. Ogura ◽

K. Hatake ◽

Y. Kobayashi ◽

M. Mori ◽

...

Keyword(s):

Phase I ◽

B Cell ◽

Hodgkin Lymphoma ◽

Japanese Patients ◽

Non Hodgkin Lymphoma ◽

Pharmacokinetics Study ◽

Cd20 Antibody ◽

Download Full-text